Jiangsu Yunyang Group Pharmaceutical Co., Ltd.

Antiviral drug. It has the effect of inhibiting the growth of many viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. This product does not change the adsorption, invasion and uncoating of viruses, nor does it induce the production of interferon. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

This product acts directly on the bronchial glands, releasing the lysosomes of mucus-secreting cells, thereby depolymerizing the mucopolysaccharides in the mucus and reducing the viscosity of the mucus; it can also cause the respiratory tract to secrete low-viscosity small-molecule mucins, making the sputum thinner and easier to cough up.

Meloxicam is a nonsteroidal anti-inflammatory analgesic (NSAID) of the enolic acid class, which has anti-inflammatory, analgesic and antipyretic effects. It exerts the above effects by inhibiting the biosynthesis of inflammatory mediators prostaglandins, and its selective inhibition of COX-2 is stronger than that of COX-1, thereby reducing the incidence of gastrointestinal and renal side effects.

This product can inhibit viral DNA and RNA polymerase, thereby inhibiting viral reproduction. On human embryonic kidney cells, 1% concentration has a significant inhibitory effect on DNA viruses (adenovirus, herpes virus) and RNA viruses (echovirus), and has an inhibitory effect on all stages of the viral proliferation cycle. It has no direct effect on free viral particles.

This product is a broad-spectrum antibiotic, the mechanism of action is to inhibit bacterial protein synthesis, and is effective against most Gram-negative and some Gram-positive bacteria, as well as Chlamydia trachomatis and Rickettsia.